Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology/Urology
Disease Category: Renal Cell Carcinoma

Trial Information

Study VEG108844, a Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Patient Inclusion Criteria:

• Diagnosis of renal cell carcinoma with clear-cell component histology.
• Received no prior systemic therapy (interleukin-2, interferon-alpha, chemotherapy, bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI) for advanced or metastatic RCC
• Measurable disease by CT or MRI

Patient Exclusion Criteria:

• History of another malignancy (unless have been disease-free for 3 years)
• History or clinical evidence of central nervous system (CNS) metastases (unless have previously-treated CNS metastases and meet all 3 of the following criteria are: are asymptomatic, have had no evidence of active CNS metastases for >=6 months prior to enrolment, and have no requirement for steroids or enzyme-inducing anticonvulsants)
• History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months (unless had recent DVT and have been treated with therapeutic anti-coagulating agents for at least 6 weeks)

Cathy Spears, Research Manager
St. Francis Hospital and Health Centers
1500 N Albany Street, Suite 1001
Beech Grove, IN 46107
Phone: 317-782-7819
Fax: 317-782-7828
EMail: cathy.spears@ssfhs.org

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.